Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Relation of cardiovascular risk factors to atherosclerosis in type III hyperlipoproteinemia

  • 35 Accesses

  • 6 Citations

Abstract

The familial lipoprotein disorder type III hyperlipoproteinemia (HPL) carries a marked increase in the risk of accelerated and premature atherosclerosis, but there is considerable variation among affected individuals in susceptibility to cardiovascular disease (CVD). We studied the influence of independent risk factors for atherosclerosis in 67 patients with clinically overt type III HPL and homozygosity for apolipoprotein (apo) E2. Among the different risk factors (lipid and lipoprotein levels, age, sex, body mass index, smoking status, hypertension, and diabetes mellitus) there was only a statistically significant difference in age between 25 patients with atherosclerosis and 42 patients without atherosclerosis. Serum lipoprotein (a), [Lp, (a)], levels were 30.6% higher in the atherosclerosis group, but this was not statistically significant. We conclude that (in contrast to familial hypercholesterolemia) elevated Lp (a) concentrations may not be regarded as a component of the clinical syndrome of type III HPL.

This is a preview of subscription content, log in to check access.

References

  1. Assmann G, Lenzen HJ (1985) Apolipoprotein E-Polymorphismus, Hyperlipidämie und Herzinfarktrisiko. Internist (Berlin) 26:692–700

  2. Berg K (1963) A new serum type in man — the Lp system. Acta Pathol Microbiol Scand 59:369–382

  3. Berg K, Dahlén G, Frick MH (1974) Lp (a) lipoprotein and prebeta1-lipoprotein in patients with coronary heart disease. Clin Genet 6:230–235

  4. Boerwinkle E (1992) Genetics of plasma lipoprotein (a) concentrations. Curr Opin Lipidol 3:128–136

  5. Boerwinkle E, Menzel HJ, Kraft HG, Utermann G (1989) Genetics of the quantitative Lp (a) lipoprotein trait III. Contribution of Lp (a) glycoprotein phenotypes to normal lipid variation. Hum Genet 82:73–78

  6. Carlson LA, Hamsten A, Asplund A (1989) Pronounced lowering of serum lipoprotein Lp (a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 226:271–276

  7. Conover WJ (1980) Practical nonparametric statistics. 2nd edn, John Wiley & Sons, New York

  8. Feussner G, Schuster H (1992) Screening for the apolipoprotein B-100 arginine3500→glutamine mutation in patients with type III hyperlipoproteinemia. Clin Genet 32:302–305

  9. Guyton JR, Dahlen GH, Patsch W, Kautz JA, Gotto AM Jr (1985) Relationship of plasma lipoprotein Lp (a) levels to race and to apolipoprotein B. Arteriosclerosis 5:265–272

  10. Havel RJ, Eder HA, Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345–1353

  11. Hazzard WR, Warnick GR, Utermann G, Albers JJ (1981) Genetic transmission of isoapolipoprotein E phenotypes in a large kindred: relationship to dysbetalipoproteinemia and hyper lipidemia. Metabolism 30:79–88

  12. Mahley RW, Rall SC Jr (1989) Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic basis of inherited disease, 6th edn. McGraw-Hill, New York, pp 1195–1235

  13. Mbewu AD, Bhatnagar D, Durrington PN, Hunt L, Ishola M, Arrol S, Mackness M, Lockley P, Miller JP (1991) Serum lipoprotein (a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb 11:940–946

  14. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL (1986) Lp (a) lipoprotein as a risk factor for myocardial infarction. JAMA 256:2540–2544

  15. Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Csásár A, Boerwinkle E, Utermann G (1991) Effects of the apolipoprotein (a) size polymorphism on the lipoprotein (a) concentration in 7 ethnic groups. Hum Genet 86:607–614

  16. Sandholzer C, Feussner G, Brunzell J, Utermann G (1992) Distribution of apolipoprotein (a) in the plasma from patients with lipoprotein lipase deficiency and with type III hyperlipoproteinemia. No evidence for a triglyceride-rich precursor of lipoprotein (a). J Clin Invest 90:1958–1965

  17. Scanu AM, Fless GM (1990) Lipoprotein (a) heterogeneity and biological relevance. J Clin Invest 85:1709–1715

  18. Schneider WJ, Kovanen PT, Brown MS, Goldstein JL, Utermann G, Weber W, Havel RJ, Kotite L, Kane JP, Innerarity TL, Mahley RW (1981) Familial dysbetalipoproteinemia: abnormal binding of mutant apolipoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenals of rats, rabbits and cows. J Clin Invest 68:1075–1085

  19. Schriewer H, Assmann G, Sandkamp M, Schulte H (1984) The relationship of lipoprotein (a) [Lp (a)] to risk factors for coronary heart disease. J Clin Chem Clin Biochem 22:591–596

  20. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G (1990) Relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 322:1494–1499

  21. Soma M, Fumagalli R, Paoletti R, Meschia M, Maini MC, Crosignani P, Ghanem K, Gaubatz J, Morrisett JD (1991) Plasma Lp (a) concentration after oestrogen and progestagen in postmenopausal women. Lancet 337:612

  22. Thiery J, Armstrong VW, Schleef J, Creutzfeld C, Creutzfeld W, Seidel D (1988) Serum lipoprotein Lp (a) concentrations are not influenced by an HMG CoA reductase inhibitor. Klin Wochenschr 66:462–463

  23. Utermann G (1987) Apolipoprotein E polymorphism in health and disease. Am Heart J 113:433–440

  24. Utermann G (1989) The mysteries of lipoprotein (a). Science 246:904–910

  25. Utermann G (1990) Genetics of the Lp (a) lipoprotein. In: Scanu AM (ed) Lipoprotein (a): 25 years of progress. Academic Press, New York, pp 75–85

  26. Utermann G, Vogelberg KH, Steinmetz A, Schoenborn W, Pruin N, Jaeschke M, Hees M, Canzler H (1979) Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III. Clin Genet 15:37–62

  27. Utermann G, Hoppichler F, Dieplinger H, Seed M, Thompson G, Boerwinkle E (1989) Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci USA 86:4171–4174

  28. Warnick GR, Mayfield C, Albers JJ, Hazzard WR (1979) Gel iso electric focusing method for specific diagnosis of familial hyperlipoproteinemia type 3. Clin Chem 25:279–284

  29. Wiklund O, Angelin B, Olofsson S-O, Eriksson M, Fager G, Berglund L, Bondjers G (1990) Apolipoprotein (a) and ischaemic heart disease in familial hypercholesterolemia. Lancet 335:1360–1363

  30. Zannis VI, Breslow JL (1981) Human very low density lipoprotein apolioprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemsitry 20:1033–1041

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Feussner, G., Wagner, A. & Ziegler, R. Relation of cardiovascular risk factors to atherosclerosis in type III hyperlipoproteinemia. Hum Genet 92, 122–126 (1993). https://doi.org/10.1007/BF00219678

Download citation

Keywords

  • Lipid
  • Body Mass Index
  • Diabetes Mellitus
  • Atherosclerosis
  • Cardiovascular Risk